HEC585

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

85 competitors in Interstitial Lung Disease

#DrugCompanyPhaseTrials

1

Rituxan

Roche

Phase 3

42

Cellcept

Roche

Phase 3

43

Actemra

Roche

Phase 3

14

Cialis

Eli Lilly

Phase 3

15

Jascayd

Boehringer Ingelheim

Phase 3

16

Prograf

VVeloxis Pharmaceuticals

Phase 3

17

Benlysta

GGlaxo Dba Glaxosmithkline

Phase 3

18

Orencia

Bristol-Myers Squibb

Phase 2

29

Elavil

AstraZeneca

Phase 2

110

Cymbalta

Alnylam Pharmaceuticals

Phase 2

1Show 37 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

IPF2 trials

Phase ll Study of HEC585 in Patients With IPF

Unknown status·Sunshine Lake Pharma Co., Ltd.·Phase 2·NCT05060822·270 enrolled

Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

Not yet recruiting·Sunshine Lake Pharma Co., Ltd.·Phase 3·NCT07082842·472 enrolled

Female2 trials

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

Completed·Sunshine Lake Pharma Co., Ltd.·Phase 1·NCT03092102·136 enrolled

Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects

Completed·Sunshine Lake Pharma Co., Ltd.·Phase 1·NCT04512170·72 enrolled

Drug Interactions1 trial

To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers

Completed·Sunshine Lake Pharma Co., Ltd.·Phase 1·NCT05383131·33 enrolled

Interstitial Lung Disease1 trial

A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients

Recruiting·Sunshine Lake Pharma Co., Ltd.·Phase 2·NCT05139719·110 enrolled

Details

Drug Info

Related News